The influence of proton pump inhibitor therapy on the clinical course of COVID-19

• Conditions: SARS-CoV2; J12.8; J80.0; Other viral pneumonia

• Registration Number: DRKS00021523
• Lead Sponsor: niversitätsklinikum Freiburg, Klinik für Innere Medizin II

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-04-27
• Study Completion: 2020-07-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 152

Inclusion Criteria

Confirmed SARS-CoV2- infection, hospitalized patients

Exclusion Criteria

SARS-CoV2 infection excluded, outpatient treatment

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Prevalence of bacterial superinfection in patienst with and without proton pump inhibitor (PPI) treatment. <br>2. Development of ARDS in patients with and without PPI treatment.

Secondary Outcome Measures

Name	Time	Method
1. Index mortality<br>2. Prevalence of intensive care treatment in patients with and without PPI treatment<br>3. Cours eof inflammatory markers in patients with and without PPI treatment and its impact on the development of disease associated complications